Extreme hypofractionation for early prostate cancer: Biology meets technology

Cancer Treatment Reviews

Volumn 50, Issue , 2016, Pages 48-60

  De Bari, Berardino ^a   Arcangeli, Stefano ^b   Ciardo, Delia ^c   Mazzola, Rosario ^d   Alongi, Filippo ^d   Russi, Elvio G ^e   Santoni, Riccardo ^f   Magrini, Stefano M ^g   Jereczek Fossa, Barbara A ^c,h  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^d SACRO CUORE DON CALABRIA HOSPITAL   (Italy)

^e S CROCE E CARLE HOSPITAL   (Italy)

^f TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^g UNIVERSITY OF BRESCIA   (Italy)

^h UNIVERSITY OF MILAN   (Italy)

Author keywords

Extreme hypofractionation; Outcome evaluation; Primary prostate cancer; Quality of life assessment; Stereotactic body radiation therapy; Toxicity evaluation

Indexed keywords

CANCER RADIOTHERAPY; CLINICAL EFFECTIVENESS; CLINICAL OUTCOME; CYBERKNIFE; DISEASE SEVERITY; DOSIMETRY; EARLY CANCER; FIDUCIAL MARKER; HEALTH CARE COST; HOLMIUM LASER; HUMAN; HYPOFRACTIONATED RADIOTHERAPY; IMAGE GUIDED RADIOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; LINEAR ACCELERATOR; MULTICENTER STUDY (TOPIC); NEPHROTOXICITY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIMARY TUMOR; PROSTATE CANCER; QUALITY OF LIFE ASSESSMENT; RADIATION DETECTION; RADIATION INJURY; RADIATION TOLERANCE; RADIOBIOLOGY; RADIOSURGERY EQUIPMENT; RADIOTHERAPY UNIT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REAL TIME TRACKING SYSTEM; RECTUM DISEASE; REVIEW; SHORT COURSE THERAPY; SPACER BALLOON; STEREOTACTIC BODY RADIATION THERAPY; STEREOTACTIC DEVICE; TOMOTHERAPY SYSTEM; TREATMENT DURATION; TREATMENT PLANNING; DISEASE FREE SURVIVAL; MALE; PROCEDURES; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOSURGERY; RECTAL DISEASES; TREATMENT OUTCOME; UROLOGIC DISEASES;

DISEASE-FREE SURVIVAL; DOSE HYPOFRACTIONATION; HUMANS; MALE; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOSURGERY; RECTAL DISEASES; TREATMENT OUTCOME; UROLOGIC DISEASES;

EID: 84986882192     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2016.08.005     Document Type: Review

References (105)

1. [1] Attard, G., Parker, C., Eeles, R.A., Schröder, F., Tomlins, S.A., Tannock, I., et al. Prostate cancer. Lancet 387:10013 (2016), 70–82, 10.1016/S0140-6736(14)61947-4 Epub 2015 Jun 11.
2. [2] Torre, L.A., Siegel, R.L., Ward, E.M., Jemal, A., et al. Global cancer incidence and mortality rates and trends—an update. Cancer Epidemiol Biomarkers Prev 25:1 (2016), 16–27, 10.1158/1055-9965.EPI-15-0578 Epub 2015 Dec 14.
3. [3] Heidenreich, A., Bastian, P.J., Bellmunt, J., Bolla, M., Joniau, S., van der Kwast, T., et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 65:1 (2014), 124–137, 10.1016/j.eururo.2013.09.046 Epub 2013 Oct 6.
4. [4] Roach, M. 3rd, Ceron Lizarraga, T.L., Lazar, A.A., et al. Radical prostatectomy versus radiation and androgen deprivation therapy for clinically localized prostate cancer: how good is the evidence?. Int J Radiat Oncol Biol Phys 93:5 (2015), 1064–1070, 10.1016/j.ijrobp.2015.08.005 Epub 2015 Nov 11.
5. [5] Wolff, R.F., Ryder, S., Bossi, A., Briganti, A., Crook, J., Henry, A., et al. A systematic review of randomised controlled trials of radiotherapy for localised prostate cancer. Eur J Cancer 51:16 (2015), 2345–2367, 10.1016/j.ejca.2015.07.019 Epub 2015 Aug 5.
6. [6] Lukka, H., Hayter, C., Julian, J.A., Warde, P., Morris, W.J., Gospodarowicz, M., et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol 23 (2005), 6132–6138.
7. [7] Yeoh, E.E., Botten, R.J., Butters, J., Di Matteo, A.C., Holloway, R.H., Fowler, J., Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. Int J Radiat Oncol Biol Phys 81 (2011), 1271–1278.
8. [8] Pollack, A., Walker, G., Horwitz, E.M., Price, R., Feigenberg, S., Konski, A.A., et al. Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol 31 (2013), 3860–3868.
9. [9] Arcangeli, G., Saracino, B., Gomellini, S., Petrongari, M.G., Arcangeli, S., Sentinelli, S., et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys 78 (2010), 11–18.
10. [10] Aluwini, S., Pos, F., Schimmel, E., Krol, S., van der Toorn, P.P., de Jager, H., et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised non-inferiority phase 3 trial. Lancet Oncol, 2016, 10.1016/S1470-2045(15)00567-7 pii: S1470–2045(15)00567-7.
11. [11] Wilkins, A., Mossop, H., Syndikus, I., Khoo, V., Bloomfield, D., Parker, C., et al. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol 16:16 (2015), 1605–1616, 10.1016/S1470-2045(15)00280-6.
12. [12] Proust-Lima, C., Taylor, J.M., Sécher, S., Sandler, H., Kestin, L., Pickles, T., et al. Confirmation of a low α/β ratio for prostate cancer treated by external beam radiation therapy alone using a post-treatment repeated-measures model for PSA dynamics. Int J Radiat Oncol Biol Phys 79:1 (2011), 195–201.
13. [13] Miralbell, R., Roberts, S.A., Zubizarreta, E., Hendry, J.H., et al. Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: a/b = 1.4 (0.9–2.2) Gy. Int J Radiat Oncol Biol Phys 82 (2012), e17–e24.
14. [14] Dasu, A., Toma-Dasu, I., et al. Prostate alpha/beta revisited an analysis of clinical results from 14168 patients. Acta Oncol 51:8 (2012), 963–974.
15. [15] Fowler, J.F., et al. The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol 62 (1989), 679–694.
16. [16] Peeters, S.T., Heemsbergen, W.D., Koper, P.C., van Putten, W.L., Slot, A., Dielwart, M.F., et al. Dose–response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24 (2006), 1990–1996.
17. [17] Pollack, A., Zagars, G.K., Starkschall, G., Antolak, J.A., Lee, J.J., Huang, E., et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53 (2002), 1097–1105.
18. [18] Zietman, A.L., DeSilvio, M.L., Slater, J.D., Rossi, C.J. Jr, Miller, D.W., Adams, J.A., et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 294 (2005), 1233–1239.
19. [19] Kuban, D.A., Tucker, S.L., Dong, L., Starkschall, G., Huang, E.H., Cheung, M.R., et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70 (2008), 67–74.
20. [20] Dearnaley, D.P., Jovic, G., Syndikus, I., Khoo, V., Cowan, R.A., Graham, J.D., et al. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomized controlled trial. Lancet Oncol 15:4 (2014), 464–473, 10.1016/S1470-2045(14)70040-3.
21. [21] Brenner, D.J., Hall, E.J., et al. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 43 (1999), 1095–1101.
22. [22] Tree, A.C., Khoo, V.S., van As, N.J., Partridge, M., et al. Is biochemical relapse-free survival after profoundly hypofractionated radiotherapy consistent with current radiobiological models?. Clin Oncol (R Coll Radiol) 26:4 (2014), 216–229, 10.1016/j.clon.2014.01.008 Epub 2014 Feb 12.
23. [23] Clemente, S., Nigro, R., Oliviero, C., Marchioni, C., Esposito, M., Giglioli, F.R., et al. Role of the technical aspects of hypofractionated radiation therapy treatment of prostate cancer: a review. Int J Radiat Oncol Biol Phys 91:1 (2015), 182–195, 10.1016/j.ijrobp.2014.08.006.
24. [24] Koontz, B.F., Bossi, A., Cozzarini, C., Wiegel, T., D'Amico, A., et al. A systematic review of hypofractionation for primary management of prostate cancer. Eur Urol 68:4 (2015), 683–691, 10.1016/j.eururo.2014.08.009 Epub 2014 Sep 22.
25. [25] Nahum, A.E., et al. The radiobiology of hypofractionation. Clin Oncol (R Coll Radiol) 27:5 (2015), 260–269, 10.1016/j.clon.2015.02.001 Epub 2015 Mar 18.
26. [26] Park, C., Papiez, L., Zhang, S., Story, M., Timmerman, R.D., et al. Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy. Int J Radiat Oncol Biol Phys, 70(3), 2008, 847e852.
27. [27] Vogelius, I.R., Bentzen, S.M., et al. Meta-analysis of the alpha/beta ratio for prostate cancer in the presence of an overall time factor: bad news, good news, or no news?. Int J Radiat Oncol Biol Phys 85:1 (2013), 89–94, 10.1016/j.ijrobp.2012.03.004 Epub 2012 May 30.
28. [28] Dearnaley, D., Syndikus, I., Mossop, H., Khoo, V., Birtle, A., Bloomfield, D., et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol, 2016, 10.1016/S1470-2045(16)30102-4 pii: S1470-2045(16)30102-4.
29. [29] Incrocci, L., Wortel, R.C., Alemayehu, W.G., Aluwini, S., Schimmel, E., Krol, S., et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol, 2016, 10.1016/S1470-2045(16)30070-5 pii: S1470-2045(16)30070-5.
30. [30] Henderson, D.R., Tree, A.C., van As, N.J., et al. Stereotactic body radiotherapy for prostate cancer. Clin Oncol (R Coll Radiol) 27:5 (2015), 270–279, 10.1016/j.clon.2015.01.011 Epub 2015 Feb 21.
31. [31] Round, C.E., Williams, M.V., Mee, T., Kirkby, N.F., Cooper, T., Hoskin, P., et al. Radiotherapy demand and activity in England 2006–2020. Clin Oncol (R Coll Radiol) 25:9 (2013), 522–530, 10.1016/j.clon.2013.05.005.
32. [32] Collins, C.D., Lloyd-Davies, R.W., Swan, A.V., et al. Radical external beam radiotherapy for localised carcinoma of the prostate using a hypofractionation technique. Clin Oncol (R Coll Radiol) 3:3 (1991), 127–132.
33. [33] De Bari, B., Daidone, A., Alongi, F., et al. Is high dose rate brachytherapy reliable and effective treatment for prostate cancer patients? A review of the literature. Crit Rev Oncol Hematol 94:3 (2015), 360–370, 10.1016/j.critrevonc.2015.02.003 Epub 2015 Feb 17.
34. [34] Leksell, L., et al. The stereotactic method and radiosurgery of the brain. Acta Chir Scand 102 (1951), 316–319.
35. [35] Franco, P., De Bari, B., Ciammella, P., Fiorentino, A., Chiesa, S., Amelio, D., et al. The role of stereotactic ablative radiotherapy in oncological and non-oncological clinical settings: highlights from the 7th Meeting of AIRO–Young Members Working Group (AIRO Giovani). Tumori 100:6 (2014), e214–e219, 10.1700/1778.19280.
36. [36] De Bari, B., Fiorentino, A., Arcangeli, S., Franco, P., D'Angelillo, R.M., Alongi, F., From radiobiology to technology: what is changing in radiotherapy for prostate cancer. Expert Rev Anticancer Ther 14:5 (2014), 553–564.
37. [37] Fawaz, Z.S., Yassa, M., Nguyen, D.H., Vavassis, P., et al. Fiducial marker implantation in prostate radiation therapy: complication rates and technique. Cancer Radiother 18 (2014), 736–739.
38. [38] Langenhuijsen, J.F., van Lin, E.N., Kiemeney, L.A., van der Vight, L.P., McColl, G.M., Visser, A.G., et al. Ultrasound-guided transrectal implantation of gold markers for prostate localization during external beam radiotherapy: complication rate and risk factors. Int J Radiat Oncol Biol Phys 69 (2007), 671–676.
39. [39] Igdem, S., Akpinar, H., Alco, G., Agacayak, F., Turkan, S., Okkan, S., et al. Implantation of fiducial markers for image guidance in prostate radiotherapy: patient-reported toxicity. Br J Radiol 82 (2009), 941–945.
40. [40] Gill, S., Li, J., Thomas, J., Bressel, M., Thursky, K., Styles, C., et al. Patient-reported complications from fiducial marker implantation for prostate image-guided radiotherapy. Br J Radiol 85 (2012), 1011–1017.
41. [41] Loh, J., Baker, K., Sridharan, S., Greer, P., Wratten, C., Capp, A., et al. Infections after fiducial marker implantation for prostate radiotherapy: are we underestimating the risks?. Radiat Oncol, 10, 2015, 38.
42. [42] Moman, M.R., van der Heide, U.A., Kotte, A.N., van Moorselaar, R.J., Bol, G.H., Franken, S.P., et al. Long-term experience with transrectal and transperineal implantations of fiducial gold markers in the prostate for position verification in external beam radiotherapy; feasibility, toxicity and quality of life. Radiother Oncol 96 (2010), 38–42.
43. [43] Ng, M., Brown, E., Williams, A., Chao, M., Lawrentschuk, N., Chee, R., Fiducial markers and spacers in prostate radiotherapy: current applications. BJU Int 113:Suppl 2 (2014), 13–20.
44. [44] Kably, I., Bordegaray, M., Shah, K., Salsamendi, J., Narayanan, G., et al. Single-center experience in prostate fiducial marker placement: technique and midterm follow-up. J Vasc Interv Radiol 25 (2014), 1125–1132.
45. [45] Udrescu, C., De Bari, B., Rouvière, O., Ruffion, A., Michel-Amadry, G., Jalade, P., et al. Does hormone therapy modify the position of the gold markers in the prostate during irradiation? A daily evaluation with kV-images. Cancer Radiother 17:3 (2013), 215–220.
46. [46] Mantz, C., et al. A phase II trial of stereotactic ablative body radiotherapy for low-risk prostate cancer using a non-robotic linear accelerator and real-time target tracking: report of toxicity, quality of life, and disease control outcomes with 5-year minimum follow-up. Front Oncol, 14(4), 2014, 279.
47. [47] Mok, G., Benz, E., Vallee, J., Miralbell, R., Zilli, T., et al. Optimization of radiation therapy techniques for prostate cancer with prostate-rectum spacers: a systematic review. Int J Radiat Oncol Biol Phys 90:2 (2014), 278–288, 10.1016/j.ijrobp.2014.06.044.
48. [48] Loblaw, A., Cheung, P., D'Alimonte, L., Deabreu, A., Mamedov, A., Zhang, L., et al. Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: toxicity, biochemical, and pathological outcomes. Radiother Oncol 107 (2013), 153–158.
49. [49] Prada, P.J., Gonzalez, H., Menéndez, C., Llaneza, A., Fernández, J., Santamarta, E., et al. Transperineal injection of hyaluronic acid in the anterior perirectal fat to decrease rectal toxicity from radiation delivered with low-dose-rate brachytherapy for prostate cancer patients. Brachytherapy 8 (2009), 210–217.
50. [50] Wilder, R.B., Barme, G.A., Gilbert, R.F., Holevas, R.E., Kobashi, L.I., Reed, R.R., et al. Cross-linked hyaluronan gel reduces the acute rectal toxicity of radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 77 (2010), 824–830.
51. [51] Noyes, W.R., Hosford, C.C., Schultz, S.E., et al. Human collagen injections to reduce rectal dose during radiotherapy. Int J Radiat Oncol Biol Phys 82 (2012), 1918–1922.
52. [52] Mariados, N., Sylvester, J., Shah, D., Karsh, L., Hudes, R., Beyer, D., et al. Hydrogel spacer prospective multicenter randomized controlled pivotal trial: dosimetric and clinical effects of perirectal spacer application in men undergoing IG-IMRT. Int J Radiat Oncol Biol Phys 92 (2015), 971–977.
53. [53] Both, S., Wang, K.K., Plastaras, J.P., Deville, C., Bar, Ad.V., Tochner, Z., et al. Real-time study of prostate intrafraction motion during external beam radiotherapy with daily endorectal balloon. Int J Radiat Oncol Biol Phys 81:5 (2011), 1302–1309.
54. [54] D'Amico, A.V., Manola, J., Loffredo, M., Lopes, L., Nissen, K., O'Farrell, D.A., et al. A practical method to achieve prostate gland immobilization and target verification for daily treatment. Int J Radiat Oncol Biol Phys 51 (2001), 1431–1436.
55. [55] Van Lin, E.N., van der Vight, L.P., Witjes, J.A., Huisman, H.J., Leer, J.W., Visser, A.G., The effect of an endorectal balloon and off-line correction on the interfraction systematic and random prostate position variations: a comparative study. Int J Radiat Oncol Biol Phys 61 (2005), 278–288.
56. [56] Court, L.E., D'Amico, A.V., Kadam, D., Cormack, R., et al. Motion and shape change when using an endorectal balloon during prostate radiation therapy. Radiother Oncol 81 (2006), 184–189.
57. [57] Wang, C.W., Chong, F.C., Lai, M.K., Pu, Y.S., Wu, J.K., Cheng, J.C., Set-up errors due to endorectal balloon positioning in intensity modulated radiation therapy for prostate cancer. Radiother Oncol 84 (2007), 177–184.
58. [58] Smeenk, R.J., Teh, B.S., Butler, E.B., van Lin, E.N., Kaanders, J.H., et al. Is there a role for endorectal balloons in prostate radiotherapy? A systematic review. Radiother Oncol 95:3 (2010), 277–282, 10.1016/j.radonc.2010.04.016 Epub 2010 May 5.
59. [59] Ahmad, S., Vlachaki, M.T., Teslow, T.N., Amosson, C.M., McGary, J., Teh, B.S., et al. Impact of setup uncertainty in the dosimetry of prostate and surrounding tissues in prostate cancer patients treated with Peacock/IMRT. Med Dosim 30 (2005), 1–7.
60. [60] Vlachaki, M.T., Teslow, T.N., Ahmad, S., et al. Impact of endorectal balloon in the dosimetry of prostate and surrounding tissues in prostate cancer patients treated with IMRT. Med Dosim 32 (2007), 281–286.
61. [61] Patel, R.R., Orton, N., Tomé, W.A., Chappell, R., Ritter, M.A., et al. Rectal dose sparing with a balloon catheter and ultrasound localization in conformal radiation therapy for prostate cancer. Radiother Oncol 67 (2003), 285–294.
62. [62] Sanghani, M.V., Ching, J., Schultz, D., Cormack, R., Loffredo, M., McMahon, E., et al. Impact on rectal dose from the use of a prostate immobilization and rectal localization device for patients receiving dose escalated 3D conformal radiation therapy. Urol Oncol 22 (2004), 165–168.
63. [63] Van Lin, E.N., Kristinsson, J., Philippens, M.E., de Jong, D.J., van der Vight, L.P., Kaanders, J.H., et al. Reduced late rectal mucosal changes after prostate three-dimensional conformal radiotherapy with endorectal balloon as observed in repeated endoscopy. Int J Radiat Oncol Biol Phys 67 (2007), 799–811.
64. [64] Goldner, G., Tomicek, B., Becker, G., Geinitz, H., Wachter, S., Zimmermann, F., et al. Proctitis after external-beam radiotherapy for prostate cancer classified by Vienna Rectoscopy Score and correlated with EORTC/RTOG score for late rectal toxicity: results of a prospective multicenter study of 166 patients. Int J Radiat Oncol Biol Phys 67 (2007), 78–83.
65. [65] Goldner, G., Bombosch, V., Geinitz, H., Becker, G., Wachter, S., Glocker, S., et al. Moderate risk-adapted dose escalation with three-dimensional conformal radiotherapy of localized prostate cancer from 70 to 74 Gy. First report on 5-year morbidity and biochemical control from a prospective Austrian-German multicenter phase II trial. Strahlenther Onkol 185 (2009), 94–100.
66. [66] Woel, R., Beard, C., Chen, M.H., Hurwitz, M., Loffredo, M., McMahon, E., et al. Acute gastrointestinal, genitourinary, and dermatological toxicity during dose-escalated 3D-conformal radiation therapy (3DCRT) using an intrarectal balloon for prostate gland localization and immobilization. Int J Radiat Oncol Biol Phys 62 (2005), 392–396.
67. [67] D'Amico, A.V., Manola, J., McMahon, E., Loffredo, M., Lopes, L., Ching, J., et al. A prospective evaluation of rectal bleeding after dose-escalated three-dimensional conformal radiation therapy using an intrarectal balloon for prostate gland localization and immobilization. Urology 67 (2006), 780–784.
68. [68] Slater, J.D., Rossi, C.J. Jr, Yonemoto, L.T., Bush, D.A., Jabola, B.R., Levy, R.P., et al. Proton therapy for prostate cancer: the initial Loma Linda University experience. Int J Radiat Oncol Biol Phys 59 (2004), 348–352.
69. [69] Boike, T.P., Lotan, Y., Cho, L.C., Brindle, J., DeRose, P., Xie, X.J., et al. Phase I dose-escalation study of SBRT for low- and intermediate-risk prostate cancer. J Clin Oncol 29:15 (2011), 2020–2026.
70. [70] King, M., Lehmann, C.R., Adler, J., et al. CyberKnife radiotherapy for localized prostate cancer: rationale and technical feasibility. Technol Cancer Res Treat 2 (2003), 25–29.
71. [71] Hossain, S., Xia, P., Huang, K., et al. Dose gradient near target-normal structure interface for nonisocentric cyberknife and isocentric intensity-modulated body RT for prostate cancer. Int J Radiat Oncol Biol Phys 78:1 (2010), 58–63.
72. [72] Fuller, D.B., Naitoh, J., Lee, C., Hardy, S., Jin, H., et al. Virtual HDR CyberKnife treatment for localized prostatic carcinoma: dosimetry comparison with HDR brachytherapy and preliminary clinical observations. Int J Radiat Oncol Biol Phys 70:5 (2008), 1588–1597.
73. [73] McBride, S.M., Wong, D.S., Dombrowski, J.J., Harkins, B., Tapella, P., Hanscom, H.N., et al. Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: preliminary results of a multi-institutional phase 1 feasibility trial. Cancer 118:15 (2012), 3681–3690.
74. [74] Freeman, D.E., King, C.R., et al. Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes. Radiat Oncol, 6, 2011, 3.
75. [75] Kang, J.K., Cho, C.K., Choi, C.W., Yoo, S., Kim, M.S., Yang, K., et al. Image-guided stereotactic body radiation therapy for localized prostate cancer. Tumori 97:1 (2011), 43–48.
76. [76] King, C.R., Brooks, J.D., Gill, H., Presti, J.C. Jr., et al. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys 82:2 (2012), 877–882.
77. [77] Aluwini, S., van Rooij, P., Hoogeman, M., Kirkels, W., Kolkman-Deurloo, I.K., Bangma, C., Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: early results. Radiat Oncol, 9(8), 2013, 84.
78. [78] Bolzicco, G., Favretto, M.S., Satariano, N., Scremin, E., Tambone, C., Tasca, A., A single-center study of 100 consecutive patients with localized prostate cancer treated with stereotactic body radiotherapy. BMC Urol, 17(13), 2013, 49.
79. [79] Chen, L.N., Suy, S., Uhm, S., Oermann, E.K., Ju, A.W., Chen, V., et al. Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience. Radiat Oncol, 13(8), 2013, 58.
80. [80] Ju, A.W., Wang, H., Oermann, E.K., Sherer, B.A., Uhm, S., Chen, V.J., et al. Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer. Radiat Oncol, 31(8), 2013, 30.
81. [81] Oliai, C., Lanciano, R., Sprandio, B., Yang, J., Lamond, J., Arrigo, S., et al. Stereotactic body radiation therapy for the primary treatment of localized prostate cancer. J Radiat Oncol 2:1 (2013), 63–70.
82. [82] Arscott, W.T., Chen, L.N., Wilson, N., Bhagat, A., Kim, J.S., Moures, R.A., et al. Obstructive voiding symptoms following stereotactic body radiation therapy for prostate cancer. Radiat Oncol, 24(9), 2014, 163.
83. [83] Katz, A.J., Kang, J., et al. Quality of life and toxicity after SBRT for organ-confined prostate cancer, a 7-year study. Front Oncol, 28(4), 2014, 301, 10.3389/fonc.2014.00301.
84. [84] Janowski, E., Chen, L.N., Kim, J.S., Lei, S., Suy, S., Collins, B., et al. Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (⩾50 cm(3)). Radiat Oncol, 15(9), 2014, 241.
85. [85] Lee, S.W., Jang, H.S., Lee, J.H., Kim, S.H., Yoon, S.C., et al. Stereotactic body radiation therapy for prostate cancer patients with old age or medical comorbidity: a 5-year follow-up of an investigational study. Medicine (Baltimore), 93(28), 2014, e290.
86. [86] Tree, A.C., Ostler, P., Hoskin, P., Dankulchai, P., Nariyangadu, P., Hughes, R.J., et al. Prostate Stereotactic Body Radiotherapy - First UK Experience. Clin Oncol (R Coll Radiol) 26:12 (2014), 757–761, 10.1016/j.clon.2014.08.007.
87. [87] Madsen, B.L., Hsi, R.A., Pham, H.T., Fowler, J.F., Esagui, L., Corman, J., Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys 67 (2007), 1099–1105.
88. [88] Alongi, F., Cozzi, L., Arcangeli, S., Iftode, C., Comito, T., Villa, E., et al. Linac based SBRT for prostate cancer in 5 fractions with VMAT and flattening filter free beams: preliminary report of a phase II study. Radiat Oncol, 8, 2013, 171.
89. [89] Kim, D.W.N., Cho, L.C., Straka, C., Christie, A., Lotan, Y., Pistenmaa, D., et al. Predictors of rectal tolerance observed in a dose-escalated phase 1–2 trial of stereotactic body radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 89:3 (2014), 509–517, 10.1016/j.ijrobp.2014.03.012.
90. [90] Hoppe, B.S., Nichols, R.C., Henderson, R.H., Morris, C.G., Williams, C.R., Costa, J., et al. Erectile function, incontinence, and other quality of life outcomes following protontherapy for prostate cancer in men 60 years old and younger. Cancer 118:18 (2012), 4619–4626, 10.1002/cncr.27398 Epub 2012 Jan 17.
91. [91] Coen, J.J., Paly, J.J., Niemierko, A., Weyman, E., Rodrigues, A., Shipley, W.U., et al. Long-term quality of life outcome after proton beam monotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 82:2 (2012), e201–e209, 10.1016/j.ijrobp.2011.03.048 Epub 2011 May 27.
92. [92] Demanes, D.J., Rodriguez, R.R., Schour, L., Brandt, D., Altieri, G., et al. High-dose- rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results. Int J Radiat Oncol Biol Phys 61:5 (2005), 1306–1316.
93. [93] Frank, S.J., Pisters, L.L., Davis, J., Lee, A.K., Bassett, R., Kuban, D.A., An assessment of quality of life following radical prostatectomy, high dose external beam radiation therapy and brachytherapy iodine implantation as monotherapies for localized prostate cancer. J Urol 177:6 (2007), 2151–2156.
94. [94] King, C.R., Freeman, D., Kaplan, I., Fuller, D., Bolzicco, G., Collins, S., et al. Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. Radiother Oncol 109 (2013), 217–221.
95. [95] King, C.R., Collins, S., Fuller, D., Wang, P.C., Kupelian, P., Steinberg, M., et al. Health-related quality of life after stereotactic body radiation therapy for localized prostate cancer: results from a multi-institutional consortium of prospective trials. Int J Radiat Oncol Biol Phys 87 (2013), 939–945.
96. [96] Sanda, M.G., Dunn, R.L., Michalski, J., Sandler, H.M., Northouse, L., Hembroff, L., et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 358 (2008), 1250–1261.
97. [97] Yu, J.B., Cramer, L.D., Herrin, J., Soulos, P.R., Potosky, A.L., Gross, C.P., Stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer: comparison of toxicity. J Clin Oncol 32 (2014), 1195–1201.
98. [98] Arcangeli, S., De Bari, B., Alongi, F., et al. Toxicity of stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer: a potential comparison bias. J Clin Oncol, 32(30), 2014, 3454.
99. [99] Evans, J.R., Zhao, S., Daignault, S., Sanda, M.G., Michalski, J., Sandler, H.M., et al. Patient-reported quality of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapy. Radiother Oncol 116:2 (2015), 179–184.
100. [100] Botrel, T.E., Clark, O., Pompeo, A.C., Bretas, F.F., Sadi, M.V., Ferreira, U., et al. Hypofractionated external-beam radiation therapy (HEBRT) versus conventional external-beam radiation (CEBRT) in patients with localized prostate cancer: a systematic review and meta-analysis. Core Evid 8 (2013), 1–13.
101. [101] Available at https://clinicaltrials.gov/. Accessed online on 30/04/2016.
102. [102] Available at http://www.isrctn.com/ISRCTN45905321. Accessed online on 30/04/2016.
103. [103] Baker, B.R., Basak, R., BMohiuddinand, J.J., Chen, R.C., et al. Use of stereotactic body radiotherapy for prostate cancer in the United States from through 2012. Cancer, 2016, 2004, 10.1002/cncr.30034.
104. [104] National Comprehensive Cancer Network (NCCN) guidelines. Available online on the website http://www.nccn.org/index.asp. Accessed online on 27/03/2016.
105. [105] Antognoni, P., Bertoni, F., D'Angelillo, R.M., Jereczek-Fossa, B.A., Magrini, S.M., Santoni, R., Linee Guida AIRO 2016: Carcinoma della Prostata. Tumori, 1 July 2016 special issue.